🟢 Damora Therapeutics is trading 6.5% up in pre-market after Guggenheim raised its price target to $60

Damora Therapeutics is trading 6.5% up at $22.00 before the September 28, 2026 open, with Guggenheim’s price-target increase a plausible company-specific catalyst. - Guggenheim raised its target to $60 from $40 and maintained a Buy rating, citing a higher mCALR antibody sales outlook; the report was published September 25 and updated September 27. - The prior close was $20.66 on September 25. No separate September 28 company announcement was identified. - Available reporting does not provide reliable current pre-market volume.